Alzheimer's, an Italian study changes strategy and bets on an intelligent protein - L'Unione Sarda.it

Alzheimer's, the Italian research changes its plan and bets on a smart protein.3 minutes and ... - L'Unione Sarda.it

Alzheimer's, an Italian study changes its strategy and relies on an intelligent protein

CNR researchers from Pozzuoli aim to strengthen the body's defenses against neurodegenerative disease. If you want to follow the news, please join our WhatsApp channel.

A radically changing perspective on solving a problem that was considered intractable.This is the pan-Italian approach, researchers at the Institute of Biomolecular Chemistry of the National Research Council of Pozzuoli (Cnr-Icb) are trying to fight one of the main human battles against Alzheimer's disease.In fact, the Campania team's new strategy focuses not on removing protein plaques from the brain, which are thought to be the cause of the disease, but on enhancing the body's natural defenses by developing a small "smart" molecule.

The research, carried out in collaboration with the Department of Biology of the University of Naples Federico II, Campus Bio-Medico of the University of Rome and the IRCCS Fondazione Santa Lucia, is published in the Journal of Neuroinflammation and describes the development of Sulfavant A, a synthetic compound patented by Cnr and already studied for its ability to fight the body against the tumor, improve the natural defense and fight the tumor. Pathogens like bacteria.

In preclinical models, sulfavant A has been shown to selectively regulate the activity of microglia, the nervous system's immune cells responsible for monitoring and removing cellular debris and protein aggregates.This aspect is particularly relevant in Alzheimer's disease, in which extracellular accumulation of beta-amyloid peptides can aggregate into plaques, contributing to neurotoxicity and neuronal loss: the pathognomonic hallmark of Alzheimer's disease, the most common neurodegenerative disease today.form.

In this context, treatment with sulfavent A reduces and partially prevents the formation of plaques, which leads to a protective effect on neurons and subsequent improvement of memory function.Overall, the results open promising perspectives for new therapeutic strategies in Alzheimer's disease and, in general, in other neurodegenerative diseases.

Angelo Fontana, director of the CNR-ICB and coordinator of the scholarly team, does not hide his conviction: “This work proposes a real change of perspective in the treatment of the disease, that is, not focusing only on the direct removal of amyloid plaques, but on supporting and strengthening the brain's endogenous defense mechanisms, with a special focus on the role of immunity. Our research is one aimed at strengthening the function of microglia, resident immune cells in the central nervous system responsible for monitoring"Alternative approaches use the removal of cellular debris and beta-amyloid protein aggregates, including early forms formed before the onset of pathological symptoms", explains Fontana.Especially on the direct destruction of deposits».

However, doctors are not fooled."Despite recent advances, the treatments available today are still limited, making the development of new methods capable of early intervention in the disease process a priority".

The research has been shown how to be sulfant and change microgliaal, increasing his phagocyic power in the first."In Prespinical features of Alzheimer's disease, keeping with Sufavant and aim of the Deground Detecular Neuroscive Recommendation Audit of the CampusBO-MEDICA FIDA University of Rome - Right by University of Fredzi University of Fredzi University of Romezi University of Romezi University of Rome."The data indicates the support of microglial, including directly in the Amoloid, can help restore a priyiological balance."

The results show that strengthening the brain's natural defenses is a promising treatment that is compatible with traditional approaches."With European funding and support from the Campania region, this research will now progress to clinical validation, but we also hope to engage private partners to develop safe and effective therapeutic interventions for Alzheimer's disease."